SYNCOM FORMULATIONS (INDIA)
Back to Cashflow Statement
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-68 Cr | ₹-15 Cr | ₹35 Cr | ₹8.29 Cr | ₹4.67 Cr |
What is the latest Cash Flow from Financing Activities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2025 | ₹-68 Cr |
| Mar2024 | ₹-15 Cr |
| Mar2023 | ₹35 Cr |
| Mar2022 | ₹8.29 Cr |
| Mar2017 | ₹4.67 Cr |
How is Cash Flow from Financing Activities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2025 | ₹-68 Cr | Negative | |
| Mar2024 | ₹-15 Cr | Negative | |
| Mar2023 | ₹35 Cr | 321.95 | |
| Mar2022 | ₹8.29 Cr | 77.66 | |
| Mar2017 | ₹4.67 Cr | - | |
Compare Cash Flow from Financing Activities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,233.3 Cr | -3.2% | 7.5% | -25.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹413,753.0 Cr | 1.5% | 5.5% | 0.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,032.0 Cr | 2.3% | 3.6% | 7.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹143,426.0 Cr | -0.5% | 5.3% | 40.2% | Stock Analytics | |
| CIPLA | ₹108,360.0 Cr | -1.1% | -2.2% | -8.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,859.0 Cr | 0.9% | 5.2% | 7% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | -3.2% |
7.5% |
-25.4% |
| SENSEX | 0.2% |
1.1% |
8.8% |
You may also like the below Video Courses